MBNL protein expression enhancing antagomiR / University of Valencia - LARVOL DELTA

Bioengineeredin vitro3D model of myotonic dystrophy type 1 human skeletal muscle. (PubMed, Biofabrication) - "AntagomiR-23b treatment rescues both molecular DM1 hallmarks and structural phenotype, restoring myotube diameter to healthy control sizes. Overall, these new microtissues represent an improvement over conventional cell culture models and can be used as biomimetic platforms to establish preclinical studies for myotonic dystrophy."

Journal • Genetic Disorders • Muscular Dystrophy • Myositis • Myotonic Dystrophy • MIR23b

The University of Valencia and ASEM, together in an R&D project for myotonic dystrophy type 1 (ConSalud.es) - "The University of Valencia and the Spanish Federation of Neuromuscular Diseases (ASEM Federation) have signed a consortium agreement within the framework of the TATAMI Project , whose objective is the development of a new therapeutic approach to the disease....The University of Valencia and different entities related to the study and attention to Myotonic Dystrophy type 1 have signed a consortium agreement that establishes cooperation in the development of this new therapeutic approach to the disease."

Licensing / partnership